Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) was featured in a recent H.C. Wainwright Key Opinion Leader event focused on oncolytic immunotherapies in breast and pancreatic cancers. The event highlighted discussions from two prominent experts:
Dr. Martine Piccart, Honorary Professor at Université Libre de Bruxelles and Scientific Director at Institut Jules Bordet, provided insights on HR+/HER2- metastatic breast cancer and emphasized the potential of pelareorep in activating immune responses against cancer.
Dr. Alexander Eggermont, Professor at University Medical Center Utrecht, discussed current treatment standards for pancreatic ductal adenocarcinoma (PDAC) and explored pelareorep's potential impact in treating this resistant form of cancer.
Details
News Market Reaction – ONCY
The recorded move for ONCY in the trading session of this news was -3.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Martine Piccart, M.D., Ph.D., an Honorary Professor of Oncology at the Université Libre de
Alexander Eggermont, M.D., Ph.D., Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht in
A replay of the full conversation can be found by clicking here.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track Designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-and-pelareorep-discussed-during-recent-hc-wainwright-key-opinion-leader-event-on-oncolytic-immunotherapies-in-breast-and-pancreatic-cancers-302425541.html
SOURCE Oncolytics Biotech® Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.